Literature DB >> 8300199

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

M Warny1, J P Vaerman, V Avesani, M Delmée.   

Abstract

This study investigated whether differences in fecal and serum antitoxin A antibody levels may account for the duration of Clostridium difficile-associated diarrhea (CDAD) and the occurrence of relapses. By an enzyme linked-immunosorbent assay, we tested 40 patients with CDAD including 25 patients without immunodeficiency and 15 patients receiving antineoplastic drugs. Two hundred eighty serum samples and 80 normal stool samples were investigated as controls. In nonimmunocompromised patients, serum immunoglobulin (IgG) and fecal IgA antitoxin A antibody titers were significantly higher in patients who suffered a single episode (n = 21) than in those with relapsing CDAD (n = 4) whose titers were at control levels. Of these 25 patients, eight suffered from diarrhea which lasted for more than 2 weeks. These patients had significantly lower serum- and feces-specific antibody levels than the others who presented symptoms of shorter duration. In cytostatic-treated patients, antitoxin A antibody levels were similar to controls, but relapses occurred in a single case. These data suggest an association between a defective humoral response to toxin A and a more severe form of C. difficile infection. They also indicate that other host-related factors control the severity of CDAD and remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300199      PMCID: PMC186119          DOI: 10.1128/iai.62.2.384-389.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

2.  Influence of molecular size of IgA on its immunoassay by various techniques. II. Solid-phase radioimmunoassays.

Authors:  D L Delacroix; J P Dehennin; J P Vaerman
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

3.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  A solid phase, direct competition, radioimmunoassay for quantitation of secretory IgA in human serum.

Authors:  D L Delacroix; J P Vaerman
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

5.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

6.  Clostridium difficile toxin A in infants.

Authors:  J M Libby; S T Donta; T D Wilkins
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

7.  Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.

Authors:  J M Libby; B S Jortner; T D Wilkins
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

8.  Serum antibody response to toxins A and B of Clostridium difficile.

Authors:  R Viscidi; B E Laughon; R Yolken; P Bo-Linn; T Moench; R W Ryder; J G Bartlett
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

9.  Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement.

Authors:  J C Siffert; O Baldacini; J G Kuhry; D Wachsmann; S Benabdelmoumene; A Faradji; H Monteil; P Poindron
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  68 in total

1.  Serum antibody responses to Clostridium difficile toxin A: predictive and protective?

Authors:  C Phillips
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

3.  Measurement of faecal immunoglobulin a levels in young children.

Authors:  Carine Dion; Paul Montagne; Marie Christine Bene; Gilbert Faure
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

4.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 5.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

6.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

7.  The correlation between Clostridium-difficile infection and human gut concentrations of Bacteroidetes phylum and clostridial species.

Authors:  E Goldberg; I Amir; M Zafran; U Gophna; Z Samra; S Pitlik; J Bishara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-19       Impact factor: 3.267

8.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

9.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea.

Authors:  S S Johal; C P Lambert; J Hammond; P D James; S P Borriello; Y R Mahida
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.